Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review.
Future Sci OA
; 10(1): 2340329, 2024.
Article
in En
| MEDLINE
| ID: mdl-38817360
ABSTRACT
Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.
About 70% of newly diagnosed breast cancers belong to a specific subgroup called hormone receptor positive (HR+)/Human epidermal growth factor receptor 2 negative (HER2-). In cases with metastatic disease, doctors recommend a treatment approach combining drugs such as palbociclib along with hormonal therapy. Our review evaluates how palbociclib performs in patients in real-world practice situations, beyond clinical trial settings. We looked at two key
measures:
how long the cancer stays controlled (progression-free survival) and overall survival. The results from these real-world studies are discussed and compared to findings in clinical trials.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Future Sci OA
Year:
2024
Document type:
Article
Affiliation country:
Denmark